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Abstract. 
 
Mutations in genes encoding for the sar-
coglycans, a subset of proteins within the dystrophin–
glycoprotein complex, produce a limb-girdle muscular 
dystrophy phenotype; however, the precise role of this 
group of proteins in the skeletal muscle is not known. 
To understand the role of the sarcoglycan complex, we 
looked for sarcoglycan interacting proteins with the 
hope of ﬁnding novel members of the dystrophin–gly-
coprotein complex. Using the yeast two-hybrid method, 
we have identiﬁed a skeletal muscle-speciﬁc form of
ﬁlamin, which we term ﬁlamin 2 (FLN2), as a 
 
g
 
- and
 
d
 
-sarcoglycan interacting protein. In addition, we dem-
onstrate that FLN2 protein localization in limb-girdle 
muscular dystrophy and Duchenne muscular dystrophy 
patients and mice is altered when compared with unaf-
fected individuals. Previous studies of ﬁlamin family 
members have determined that these proteins are in-
volved in actin reorganization and signal transduction 
cascades associated with cell migration, adhesion, dif-
ferentiation, force transduction, and survival. Speciﬁ-
cally, ﬁlamin proteins have been found essential in 
maintaining membrane integrity during force applica-
tion. The ﬁnding that FLN2 interacts with the sarcogly-
cans introduces new implications for the pathogenesis 
of muscular dystrophy.
Key words: dystrophin • muscular dystrophy •
ﬁlamin C (FLNC) • cytoskeleton • cell signaling
 
Introduction
 
The muscular dystrophies are a genetically heterogeneous
group of disorders that affect muscle membrane integrity,
resulting in a loss of muscle function. The most common
form of muscular dystrophy is caused by abnormalities in
dystrophin, the protein product of the duchenne muscular
dystrophy (DMD)
 
1
 
 gene (Hoffman et al., 1987). Dystro-
phin is a large subsarcolemmal, actin-binding protein asso-
ciated with a complex of sarcolemmal and cytoskeletal
proteins known as the dystrophin–glycoprotein complex
(DGC) (Yoshida and Ozawa, 1990; Ervasti and Campbell,
1991). DGC can be separated into three subcomplexes:
(1) dystroglycan, (2) dystrobrevin–syntrophin, and (3) sar-
coglycan complexes, which together are believed to confer
structural support by providing a link between the extra-
cellular matrix (ECM) and the actin cytoskeleton (Camp-
bell and Kahl, 1989; Yoshida and Ozawa, 1990; Ervasti
and Campbell, 1993; Yoshida et al., 1994).
The pathogenic mechanism by which the muscular dys-
trophy phenotype arises remains poorly understood. As
new genes associated with this group of disorders are
discovered, the complexity of proposed mechanisms in-
creases. This phenomenon is best seen in the various limb-
girdle muscular dystrophies (LGMDs). Here, positional
cloning and candidate gene approaches have shown that at
least 14 different genetically defined disorders are re-
sponsible for the LGMD phenotype. This list includes the
 
following: sarcoglycans (
 
a
 
, 
 
b
 
, 
 
g
 
, and 
 
d
 
), 
 
a
 
7 integrin, the
calcium-dependent protease calpain-3, caveolin-3, and
dysferlin (Roberds et al., 1994; Bonnemann et al., 1995;
Lim et al., 1995; Noguchi et al., 1995; Richard et al.,
 
1995; Nigro et al., 1996; Mayer et al., 1997; Bashir et
al., 1998; Hayashi et al., 1998; Liu et al., 1998; McNally
et al., 1998; Minetti et al., 1998). Originally, it was be-
lieved that dystrophin and the dystroglycan complex
had merely a structural role in skeletal muscle by anchor-
ing muscle cells to the ECM, which would involve a more
stationary process. Although some proteins involved in
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the dystrophic process do provide structural support, the
majority of proteins associated with the phenotype are
involved in signal transduction cascades. For example,
the 
 
a
 
7 integrin subunit belongs to a family of transmem-
brane receptor proteins known to modulate gene expres-
sion specific for cell migration, adhesion, or prevention
of apoptosis (Yamada and Miyamoto, 1995; Giancotti
and Ruoslahti, 1999). M-calpain has been implicated in
regulating actin-myosin filament formation, and calpains,
in general, are thought to regulate transcription factors’
entry into the nucleus by cleavage (Kwak et al., 1993b;
Sorimachi et al., 1997; Baghdiguian et al., 1999). The ca-
veolins (types 1, 2, and 3) form vesicular invaginations
termed caveolae within the plasma membrane on which
preassembled signaling complexes are organized (Oka-
moto et al., 1998). With the cloning of these genes, it has
become evident that the process of maintaining muscle
fiber integrity is dynamic and not simply a static, struc-
tural process. The remaining proteins, including the
sarcoglycans, have no known function and intensive re-
search is being done to unravel their roles in the mainte-
nance of muscle fiber integrity.
Some clues as to the function of the sarcoglycans can be
gained through biochemical analysis. Coimmunoprecipita-
tion and chemical cross-linking studies in the skeletal mus-
cle have demonstrated the close physical association be-
tween members of the sarcoglycan complex by showing
that 
 
b
 
-, 
 
g
 
-, 
 
d
 
-, and to a lesser extent, 
 
a
 
-sarcoglycan are
tightly connected with one another (Chan et al., 1998).
Further evidence for this association is seen through im-
munofluorescence (IMF) studies using skeletal muscle
sections from sarcoglycanopathy patients and staining for
various sarcoglycans. These experiments reveal a reduc-
tion or complete absence of all four sarcoglycan proteins
at the sarcolemmal membrane, suggesting that a mutation
in any one sarcoglycan can create a secondary instability
of the entire sarcoglycan complex. Interestingly, although
mutations in dystrophin and the sarcoglycans produce a
similar phenotype, dystrophin staining in the sarcoglycan-
opathies is either normal or only slightly reduced, indicat-
ing that the selective loss of the sarcoglycan complex is
sufficient to cause muscular dystrophy (McNally et al.,
1996; Hack et al., 1998; Araishi et al., 1999).
To further study the sarcoglycan complex and the role it
plays in maintaining muscle fiber integrity, we looked for
interacting proteins with the hope of finding additional
clues as to the function of the sarcoglycan complex. Using
the yeast two-hybrid system, we tested the intracellular
domains of 
 
a
 
-, 
 
b
 
-, 
 
g
 
- and 
 
d
 
-sarcoglycans. From these li-
brary screens, we identified a skeletal and cardiac muscle
filamin (filamin 2; FLN2) as a 
 
g
 
-sarcoglycan interacting
protein, and confirmed this interaction using in vivo coim-
munoprecipitation experiments and in vitro protein as-
says. In addition to binding 
 
g
 
-sarcoglycan, we determined
that this protein also binds 
 
d
 
-sarcoglycan but not 
 
a
 
- or
 
b
 
-sarcoglycans. Through EM studies, FLN2 appears to be
located both at the Z-line and the sarcolemmal membrane
in skeletal muscle, indicating that a subpopulation of this
protein colocalizes with the DGC. Patients with muta-
tions in 
 
g
 
-sarcoglycan, 
 
d
 
-sarcoglycan, or dystrophin show
an increase of FLN2 content at the plasma membrane
compared with normal individuals and, interestingly, pa-
 
tients with general myopathy appear to have normal FLN2
staining.
Filamin proteins have been implicated as signal trans-
ducers in several systems and, therefore, might aid in the
maintenance of skeletal muscle by regulating and/or pro-
tecting the muscle during the process of muscle contrac-
tion. The identification of filamin as a sarcoglycan inter-
acting protein strengthens the idea that the DGC does not
merely function as structural support, but rather that this
group of proteins has an active role (i.e., signaling role) in
maintaining the skeletal muscle.
 
Materials and Methods
 
Two-Hybrid Library Screening
 
The cytoplasmic tails of 
 
a
 
- (amino acids 312–387), 
 
b
 
- (amino acids 1–62),
 
g
 
- (amino acids 1–38), and 
 
d
 
-sarcoglycan (amino acids 1–35) were ampli-
fied by reverse transcriptase–PCR from human skeletal muscle total RNA
with primers containing EcoRI linkers, and inserted downstream of the
Gal4 DNA-binding domain in the (bait) vector pGBT9 (CLONTECH
Laboratories). The resulting clones were sequenced and found to be in-
frame with the yeast GAL4 DNA-binding domain.
A CLONTECH yeast two-hybrid cDNA library derived from the hu-
man skeletal muscle, inserted downstream of the Gal4 activation domain
in the vector pGAD, was screened using the yeast two-hybrid protocol
(MATCHMAKER-1 system; CLONTECH Laboratories). In brief, 
 
Sac-
charomyces cerevisiae
 
 strain HF7C was cotransformed with either library
DNA plus a sarcoglycan bait vector or sequentially transformed with bait
vector followed by library DNA. The HF7C strain contains two reporter
genes, 
 
HIS3
 
 and 
 
LacZ
 
, which allow for the selection of library cDNAs en-
coding proteins that interact with the intracellular portion of the sarcogly-
cans. Transformants were plated onto SD/Trp
 
2
 
/Leu
 
2
 
/His
 
2
 
 plates and in-
cubated at 30
 
8
 
C until colonies appeared (
 
z
 
5 d). Colonies able to grow on
minimal plates were screened for 
 
b
 
-galactosidase activity using a filter-lift
assay. Yeast DNA isolated from colonies positive for 
 
b
 
-galactosidase ac-
tivity was used to electroporate 
 
Escherichia
 
 
 
coli 
 
to recover the interacting
cDNA. To eliminate false positive colonies, plasmid DNA from the
 
b
 
-galactosidase–positive clones was reintroduced into yeast with either
the sarcoglycan/pGBT9 bait vector, pGBT9 alone, or a control vector p53/
pGBT9.
 
Full-length FLN2 cDNA Cloning, DNA Sequencing, 
and Analysis
 
Sequence from a 
 
g
 
-sarcoglycan interacting clone, 2-14, was used to screen
a human skeletal muscle cDNA library (CLONTECH Laboratories) in
conjunction with two express sequence tags (ESTs) previously reported to
be muscle-specific forms of 
 
FLN1
 
 (GenBank accession numbers X70083
and X70084). The probes for X70083 and X70084 were obtained using
primers designed for the GenBank sequences to amplify cDNA from re-
verse transcribed human skeletal muscle RNA. Of 10
 
6
 
 recombinant phage
screened, 
 
z
 
200 phage clones hybridized with the presumed 
 
FLN2
 
 probes.
40 randomly picked phage clones were used to plaque purify and obtain
DNA. Phage inserts were subcloned into the EcoRI site of the pZERO1.1
vector (Invitrogen Corp.) for further characterization. Nine clones were
chosen for sequencing because of their large insert size.
All pGBT9 and pZERO1.1 subclones were sequenced from both DNA
strands using vector primers. An additional sequence on larger inserts was
obtained by designing primers to the previously obtained sequence. The
sequence was analyzed on either an ABI 373 or 377 automated sequencer
with fluorescent dye terminator chemistry (Applied Biosystems). Se-
quences were assembled using Sequencher™ 3.1 software (Genecodes).
Subsequent amino acid prediction analysis was performed using MacVec-
tor™ software (Oxford Molecular Group) and the GAP program within
the GCG database. In addition, the BLAST computer program was used
to search the GenBank database for ESTs and sequence-tagged sites con-
taining sequences similar to those in the 2-14 cDNA clone.
 
Preparation of Cell Lysates and Immunoprecipitation
 
Whole cell lysates and immunoprecipitation experiments were performed 
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as described previously (Chan et al., 1998). In brief, cultured mouse myo-
tubes were lysed on ice for 15 min in lysis buffer (50 mM Tris, pH 7.4,
150 mM NaCl, 1% NP-40, 0.1% SDS, and 1
 
3
 
 protease inhibitor cocktail)
and cell debris was pelleted by centrifugation for 10 min. Protein concen-
tration of the resulting lysate was determined by the Bio-Rad DC protein
colorimetric assay using BSA as a standard (Bio-Rad Laboratories). For
immunoprecipitation experiments, 50–100 
 
m
 
g of cell lysate was precleared
using protein G–Sepharose beads (Sigma Chemical Co.). Precleared ly-
sate was incubated with 5–10 
 
m
 
l of antisarcoglycan antibody at 4
 
8
 
C for 4 h,
and then with 15 
 
m
 
l of protein G–Sepharose beads for 1 h. The immune
complex was washed three times with cold lysis buffer and solubilized in
2
 
3
 
 protein sample buffer (Novex). Protein complexes were separated by
electrophoresis on 4–20% denaturing gradient gels (Novex) and trans-
ferred onto nitrocellulose membrane.
 
Antibody Production
 
A 511-residue polypeptide corresponding to the carboxy terminus of
FLN2 was fused in-frame to glutathione-S-transferase in the pGEX-4T1
vector using a PCR based cloning method. In brief, PCR primers designed
with EcoRI linkers were used to amplify a DNA fragment encoding
amino acids 2,128–2,688 of 
 
FLN2
 
 from the 2-14 clone and subcloned into
an EcoRI-digested pGEX-4T1 vector. The sequence was confirmed using
a 373 or 377 ABI automated sequencer. The fusion protein was purified
from 
 
E
 
. 
 
coli 
 
using B-PER bacterial protein extraction reagent (Pierce
Chemical Co.). Protein preparations were used to inject New Zealand
white rabbits for polyclonal antibody production (Covance). A second an-
tigen was generated to the unique region of FLN2 because of the overall
similarity of FLN2 to FLN1. A peptide corresponding to amino acids
2,160–2,177 (C-SKTRGGETKREVRVEEST) was synthesized and used
to inject New Zealand white rabbits (Research Genetics). The amino ter-
minal cysteine is not part of the FLN2 sequence, and was added for use in
affinity purification.
Antibodies were purified from both sets of sera using previously de-
scribed purification techniques (Harlow and Lane, 1988). For the fusion
protein antibody (FLN2-A1), the cDNA fragment encoding for the 511-
residue carboxy terminus was subcloned into the pTrcHis2-TOPO TA
cloning vector (Invitrogen Corp.). 6
 
3
 
 His
 
1
 
–tagged fusion protein was pu-
rified from 
 
E
 
.
 
 coli
 
 using His-Bind resin and buffer kit (Novagen), and was
coupled to Affi-gel 10 immunoaffinity matrix as per the manufacturer’s
instructions (Bio-Rad Laboratories). SulfoLink coupling gel (Pierce
Chemical Co.) was used to couple the 15–amino acid peptide (residues
2,160–2,177) for use in the affinity purification of the peptide antibody
FLN2-A2. Crude sera was affinity-purified over the appropriate column
using standard acid-base elution methods (Harlow and Lane, 1988). Re-
sulting affinity-purified antibodies were dialyzed against PBS, pH 7.4.
 
Immunoblot Analysis
 
Proteins were transferred to nitrocellulose membranes at room tempera-
ture (Schleicher and Schuell) in Towbin buffer at 20 V overnight (Towbin
et al., 1979). Membranes were blocked using (1
 
3
 
 PBS, 0.1% Tween 20,
and 5% nonfat milk) for 1 h at room temperature to prevent nonspecific
proteins from binding to the membranes. Membranes were incubated for
2 h at room temperature with the primary antibody diluted in blocking so-
lution. Membranes were given four, 15-min washes in 1
 
3
 
 PBS, 0.1%
Tween 20, and then incubated for 1 h with an HRP-conjugated donkey
anti–rabbit (or anti–mouse) IgG (H 
 
1 
 
L) secondary antibody (Jackson
ImmunoResearch Laboratories) diluted to 1:10,000 in blocking buffer.
Membranes were given three, 15-min washes in 1
 
3
 
 PBS, and 0.1% Tween
20. The HRP-conjugated protein complex was detected by chemilumines-
cence according to the manufacturer’s protocol (Renaissance; NEN) and
visualized on X-ray film.
 
In Vitro Transcription/Translation
 
Portions of 
 
FLN2
 
 and the sarcoglycans were subcloned into expression
vectors pMGT-1 and pFHR-3, which have been described previously in
detail (Ahn and Kunkel, 1995). [
 
35
 
S]Methionine-labeled peptides were
translated in vitro using a TNT T7 coupled reticulocyte lysate system ac-
cording to the manufacturer’s protocol (Promega Corp.). Expressed pro-
teins were separated by electrophoresis on SDS gradient gels purchased
from Novex. Gels were exposed to a storage phosphor plate that was sub-
sequently scanned using a PhosphorImager (Molecular Dynamics).
 
Microsome Preparation
 
Samples of cultured C2C12 myotubes or mouse skeletal muscle were ho-
mogenized with a Dounce homogenizer in 1 ml of ice cold buffer I (10 mM
Tris, pH 7.5, and 2 mM PMSF with protease inhibitor cocktail; Boehringer
Mannheim). After 10 min of incubation on ice, 1 ml of buffer II (10 mM
Tris, pH 7.5, 20% sucrose, 0.3 M KCl, 2 mM PMSF, and protease inhibitor
cocktail) was added to the solution and centrifuged at 12,000 
 
g
 
 at 4
 
8
 
C for 3
min. The remaining cell pellet was rehomogenized with fresh buffer I and
II. The supernatant from both rounds of homogenization was subse-
quently combined and centrifuged at 105,000 
 
g
 
 for 1 h using a Beckman
SW55Ti rotor. The final microsome pellet and the supernatant (soluble
fraction) were used in Western blot analysis.
 
Immunohistochemistry
 
Skeletal muscle was obtained under an institutional discarded tissue pro-
tocol (Children’s Hospital, Boston, MA) for short postmortem interval
autopsies of patients without neuromuscular disease. Specimens were fro-
zen in isopentane, cooled in liquid nitrogen, and stored at 
 
2
 
80
 
8
 
C until cryo-
sectioning was performed. Mounted sections of frozen muscle (8 
 
m
 
m)
were fixed in methanol for 3 min and blocked in 1
 
3
 
 PBS with 15% horse
serum and 0.1% Triton X-100 for 1 h at 4
 
8
 
C. Incubation with primary
anti–FLN2 antibodies, FLN2-A1 or FLN2-A2 (1:1,000), and antisarcogly-
can (Novocastra; 1:200) was carried out overnight at 4
 
8
 
C. The slides were
washed three times, 20 min each in 1
 
3
 
 PBS and 0.25% Triton X-100, re-
blocked for 30 min and incubated for 1 h at room temperature with a Cy3-
or FITC-conjugated donkey anti–rabbit (or anti–mouse) IgG (H 
 
1 
 
L)
secondary antibody cross-adsorbed for human IgG from Jackson Immu-
noResearch Lab (1:300). Slides were subsequently given three 20-min
washes in 1
 
3
 
 PBS and 0.25% Triton X-100, and the coverslips were
mounted using the ProLong antifade kit from Molecular Probes. Analysis
was performed using a Zeiss Axioplan II microscope. Resulting slides
were washed and the coverslips were mounted for analysis using the Zeiss
microscope with a triple filter.
 
Confocal Microscopy
 
Flash frozen needle biopsies of normal adult skeletal muscle were pre-
pared as described in the immunohistochemistry section above. Cryosec-
tions (7–8 
 
m
 
m) were cut at –20
 
8
 
C using a Microm cryostat. Frozen sections
were mounted on gelatin-coated slides blocked with 5% goat serum in
PBS containing 5% BSA, and 0.15% glycine (buffer A) for 40 min. Sec-
tions were washed three times in buffer A, and then incubated for 1 h with
FLN2-A2 antibody (1:1,000; see Antibody Production). Sections were
washed three times in buffer A, and incubated for 1 h with an Alexa 488
conjugated secondary antibody (1:500; Molecular Probes). After three
further wash steps, coverslips were mounted using gelvatol (Monsanto).
Sections were observed using a confocal laser scanning microscope (TCS
NT; Leica). Parameters, including pinhole size, PMT settings, laser inten-
sities, and magnifications (60
 
3
 
) were kept constant for all the imaging
analysis conducted. Randomly sampled areas were selected, and the abun-
dance and distribution of proteins were examined.
 
Immunoelectron Microscopy
 
Biopsies were fixed in 2% paraformaldehyde, and 0.01% glutaraldehyde,
diced into 1-mm cubes, and cryoprotected overnight in a solution contain-
ing 1
 
3
 
 PBS and 2.3 M sucrose. Subsequently, the tissue was mounted on
cutting stubs in a specific (longitudinal or cross-sectional) orientation,
shock frozen, and stored in liquid nitrogen. Thin sections (70–100 nm)
were cut using a Reichert ultracut S ultramicrotome with an FC4S cryoat-
tachment, lifted in a small drop of sucrose, and mounted on Formvar-
coated carbon grids. Sections were washed three times in PBS containing
0.5% BSA and 0.15% glycine, pH 7.4 (buffer B), followed by a 30-min in-
cubation with purified goat IgG (50 
 
m
 
g/ml) at 25
 
8
 
C and three additional
washes with buffer B. All the preceding steps were designed to ensure
minimal nonspecific reaction to the antibodies used. Sections were incu-
bated for 60 min with primary antibody, followed by three washes in
buffer B and a 60-min incubation in gold-labeled secondary antibody (a
5-nm goat anti–rabbit gold conjugate at 1–2 
 
m
 
g/ml). The sections were
given six 5-min washes in buffer B, followed by three changes in 1
 
3
 
 PBS,
and then fixed briefly in 2.5% glutaraldehyde in 1
 
3
 
 PBS to ensure that
the antibodies didn’t dissociate. After fixation, the sections were washed
three times in 1
 
3
 
 PBS, followed by five washes in water and counterstain- 
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ing with uranyl acetate. The sections were embedded in 1.25% methylcel-
lulose and analyzed using a JEOL 1210 electron microscope.
 
Results
 
Yeast Two-Hybrid Analysis
 
To identify novel proteins that interact with the sarcogly-
can complex in vivo, we screened a human skeletal muscle
yeast two-hybrid library with the intracellular domains of
 
a
 
-, 
 
b
 
-, 
 
g
 
-, and 
 
d
 
-sarcoglycans. Each sarcoglycan intracellu-
lar domain was subcloned into the pGBT9 bait vector us-
ing a PCR based method. To ensure that the pGBT9/
sarcoglycan clones alone were not able to initiate tran-
scription of the yeast reporter genes alone, each construct
was cotransformed into the yeast with the library vector
alone and tested for 
 
b
 
-galactosidase activity. None of the
sarcoglycan clones self-activated and were, therefore, used
in library screens. Each sarcoglycan subclone was trans-
formed into yeast in conjunction with a skeletal muscle
cDNA library present in the prey vector pGAD to screen
for interacting clones. Approximately 4 
 
3
 
 10
 
6
 
 colonies
were screened for 
 
a
 
- and 
 
b
 
-sarcoglycan intracellular do-
mains and 
 
z
 
2 
 
3
 
 10
 
6
 
 were screened for 
 
g
 
- and 
 
d
 
-sarcogly-
can. The 
 
g
 
-sarcoglycan library screen produced a single
clone that was HIS
 
1
 
 and positive for 
 
b
 
-galactosidase activ-
ity; however, the other sarcoglycan screens were negative.
This interacting clone, 2-14, contained a 2.5-kb insert. To
confirm the interaction between 
 
g
 
-sarcoglycan and 2-14,
we reintroduced purified 2-14 plasmid DNA into yeast
with either pGBT9/
 
g
 
-sarcoglycan bait vector, pGBT9 vec-
tor, or pGBT9/p53 control vector. Transactivation of HIS3
and LacZ was only detected with the bait vector contain-
ing 
 
g-sarcoglycan.
Although the d-sarcoglycan library screen did not iden-
tify any interacting clones, the g- and d-sarcoglycan pro-
teins share z60% sequence identity and, in fact, contain a
stretch of 15 residues in their intracellular tails of which 14
are identical (Fig. 1 A). Therefore, we tested whether
d-sarcoglycan could also interact with 2-14 in the yeast
two-hybrid system. The d-sarcoglycan intracellular domain
produced colonies on the His2 plates, and were subse-
quently tested for b-galactosidase activity. The His2 colo-
nies produced a blue color within 2 h, indicating an inter-
action between d-sarcoglycan and 2-14. In addition, we
tested the other sarcoglycans, the carboxyl terminus of
dystrophin (exons 68–78) and a syntrophin for their ability
to interact with 2-14 in yeast. No colonies grew when the
dystrophin, syntrophin, a- or b-sarcoglycan constructs
were coexpressed with 2-14, suggesting there was no inter-
action (Table I).
The 2-14 clone was sequenced using pGAD forward and
reverse vector primers, and the resulting sequence was
used to search the GenBank database BLASTP computer
program for similar sequences. Several ESTs were found
with significant protein similarity to 2-14. The greatest
homology was between 2-14 and the 39 portion of human
nonmuscle filamin FLN1 (E value 5 6 3 10249), b-filamin
(E value 5 2 3 10242), and chicken smooth muscle filamin
(E value 5 8 3 10215), with slightly lower homology to other
actin-binding proteins (thyroid autoantigen; E value 5 2 3
10–6). These similarities indicate that 2-14 is a member of
the actin-binding protein family and, more specifically, a
filamin protein family member. Because of the significant
homology with the other filamin family members, we be-
lieve that this clone corresponds to the previously de-
scribed skeletal muscle filamin, FLN2 (Wang et al., 1975;
Maestrini et al., 1993).
Comparison of FLN2 with Other Filamin
Family Members
The FLN2 clone 2-14 was used in combination with two
previously reported muscle-specific filamin-like ESTs
(GenBank/EMBL/DDBJ accession numbers X70083 and
X70084) to isolate overlapping cDNA clones for the entire
transcript. Sequence analysis determined that FLN2 has
considerable similarity and identity to the human nonmus-
cle filamins (FLN1 and b-filamin) over their entire length,
being 74/71% identical and 84/83% similar to human
FLN1 and b-filamin, respectively (data not shown). The
amino terminus actin-binding domain of FLN2 is nearly
100% identical to the actin-binding domain of both FLN1
and b-filamin, which share considerable identity to other
actin-binding proteins such as dystrophin, spectrin, and
a-actinin. Like FLN1 and b-filamin, FLN2 contains 24 re-
peating units averaging 96 amino acids in length; however,
these repeats are disrupted by two hinge regions in FLN1
and b-filamin and only one hinge region in skeletal muscle
FLN2. All three filamins contain the second hinge region
between repeats 23 and 24 but, unlike FLN1 and b-fil-
amin, skeletal muscle FLN2 does not appear to contain the
first hinge region that separates repeats 15 and 16. The
FLN2 carboxy terminus is highly similar to FLN1 and
b-filamin, which contain the binding site for several recep-
tor proteins including tissue factor receptor, b1 integrin,
b2 integrin, and the glycoprotein (GP) Ib-IX complex
(Andrews and Fox, 1991, 1992; Sharma et al., 1995; Loo et
al., 1998; Ott et al., 1998; Takafuta et al., 1998). This is con-
sistent with our data in which g- and d-sarcoglycan bind to
FLN2 in the carboxyl-terminal region between residues
2,177 and 2,688. Interestingly, FLN2 contains an 82–amino
acid unique region between repeats 19 and 20 not found in
either FLN1 or b-filamin (Fig. 1 B). In addition, b-filamin
appears to be missing eight amino acids just 59 to the first
hinge region that are present in both FLN1 and FLN2.
Protein Expression of FLN2
Previous reports of FLN2 gene expression describe a skel-
etal and cardiac muscle–specific staining pattern that we
also found (data not shown) (Maestrini et al., 1993). To
determine the protein expression pattern of FLN2 and
compare it to the expression pattern of FLN1, tissue ly-
Table I. Yeast Two-Hybrid Analysis
Construct Growth on His1 plates b-Galactosidase activity
a-Sarcoglycan 2 N/A
b-Sarcoglycan 2 N/A
g-Sarcoglycan 11
d-Sarcoglycan 11
Dystrophin (C-term) 2 N/A
a-Syntrophin 2 N/AThompson et al. Interaction of FLN2 with g- and d-Sarcoglycan 119
sates from nine different tissues were prepared and used in
Western blot analysis. To detect FLN2 protein, we gener-
ated a polyclonal antibody using a GST/FLN2 fusion
protein containing FLN2 amino acids 2,128–2,688 (see
Materials and Methods). The affinity-purified FLN2-A1
antibody detected a single band at z280 kD, and this band
was present only in the heart and skeletal muscles (Fig. 2),
which is consistent with Northern blot analysis results. In
contrast, FLN1 antibodies identified FLN1 protein in kid-
ney, lung, ovary, testis, and weakly in heart tissues but not
skeletal muscle. In addition, the FLN1 mAb detected sev-
eral smaller bands in addition to the predicted 280-kD
band (Fig. 2). FLN1 antibodies have been reported previ-
ously to detect cleavage products in some tissues (Kwak
et al., 1993a). All of the nonmuscle tissues that contain
FLN1 correspond to the previously published RNA ex-
pression pattern for both nonmuscle filamins by Northern
analysis (Takafuta et al., 1998). Interestingly, heart and
skeletal muscles do not have the abundance of FLN1 pro-
tein that corresponds to Northern data provided by other
groups for FLN1. It is possible that the cDNA probes used
to identify the FLN1 transcript in these tissues cross-
hybridize to the FLN2 message. Overall, FLN1 and FLN2
antibodies reveal distinct protein expression patterns, sug-
gesting that the FLN2 antibodies do not cross-react with
other filamin family members.
In Vitro Binding of FLN2 and the Sarcoglycans
To substantiate the yeast two-hybrid interaction between
FLN2 and the sarcoglycans, full-length g- and d-sarcogly-
cans were translated in an in vitro transcription/translation
Figure  1. Protein sequence
comparisons between g-
and  d-sarcoglycans. (A)
The alignment of g- and
d-sarcoglycans with a pre-
dicted open reading frame
from the Caenorhabditis ele-
gans cosmid F07H5.2 using
the GRAIL exon prediction
program. The protein se-
quence from the intracellular
tails of g- and d-sarcoglycans
(consisting of the first 39 and
41 amino acids, respectively)
and a predicted open reading
frame from a C. elegans were
aligned using the MacVec-
tor™ software. (B) Protein
sequence comparison of the
three filamin family mem-
bers. The carboxy terminus
of the filamins were aligned
using MacVector™ soft-
ware. The two hinge regions
are underlined. The peptide
sequence used to raise the
FLN2-A2 antibody is boxed.The Journal of Cell Biology, Volume 148, 2000 120
assay system described previously (Ahn and Kunkel, 1995)
and combined with GST/FLN2 fusion protein. Fusion pro-
tein was mixed with [35S]methionine–labeled translated
g- and d-sarcoglycans, and then precipitated using glu-
tathione beads. The results indicate that both g- and d-sar-
coglycan are precipitated using glutathione beads only
when FLN2 is present (Fig. 3 A, lanes 1 and 3). Although
there is some labeled protein found in the reactions absent
for fusion protein (lanes 2 and 4), there is considerably
more protein found in the lanes that include fusion pro-
tein, suggesting that the FLN2 fusion protein can precipi-
tate with both g- and d-sarcoglycans in this system. As
controls, labeled dystrophin (carboxy terminus) and b1-
syntrophin were also mixed with the FLN2 fusion protein;
however, FLN2 was not able to precipitate either of these
translated proteins (lanes 5–8). The supernatant from
each of the above reaction tubes shows that translated
protein was present in each tube in equal amounts (Fig. 3
B, lanes 1–8).
To confirm this interaction in another in vitro system,
we mixed in vitro translated full-length g- and d-sarcogly-
cans with in vitro translated FLN2 (clone 2-14). Translated
FLN2 was combined with each sarcoglycan individually
and these lysates were used to coimmunoprecipitate (CoIP)
either sarcoglycan or FLN2 protein using antibodies di-
rected toward either the FLN2 flag epitope (see Materials
and Methods) or the respective sarcoglycan. After the iso-
lation of immune complexes using protein G–Sepharose
and an antibody specific to either FLN2 or a sarcoglycan,
the samples were subjected to SDS-PAGE. Antibodies
specific for d-sarcoglycan were able to CoIP FLN2 and,
conversely, FLN2 antibodies coimmunoprecipitated d-sar-
coglycan (Fig. 4, lanes 1 and 4, respectively), which is con-
sistent with previous in vivo and in vitro binding data. In
contrast, antibodies directed toward g-sarcoglycan were
not able to CoIP FLN2 and, likewise, FLN2 antibodies
were not able to CoIP g-sarcoglycan (data not shown).
Specificity was shown by withholding either antibody
(lane 2) or labeled protein (lane 6). Lanes 3 and 5 (Fig. 4)
Figure 2. Western blot anal-
ysis of FLN1 and FLN2. Ap-
proximately 30 mg of total
protein lysate from several
tissues were separated by
electrophoresis on a 4–20%
gradient gel and transferred
to nitrocellulose mem-
branes. Anti–FLN1 and anti–
FLN2 (FLN2-A1) antibod-
ies were used to detect each
protein in the tissue lysates.
For FLN1, a prominent band
at  z280 kD with several
smaller bands were detected
in most nonmuscle tissues and in heart. Hydrolytic fragments
have been reported previously for FLN1. The FLN2 antibody de-
tected FLN2 protein in only skeletal and cardiac muscles and not
in the nonmuscle tissues, which is consistent with the Northern
blot results (data not shown). As a control for loading, anti–actin
antibodies were also used.
Figure 3. In vitro translated g- and d-sarcoglycan interaction with
a GST/FLN2 fusion protein. (A) 35S-labeled in vitro translated
products were mixed with a GST/FLN2 fusion protein containing
FLN2 amino acids 2,128–2,688. Lanes 1 and 2 contain translated
d-sarcoglycan protein mixed with fusion protein (lane 1) or GST
protein alone (lane 2). Lanes 3 and 4 contain translated g-sar-
coglycan mixed with fusion protein (lane 3) or GST protein alone
(lane 4). Lanes 5–8 contain either the carboxyl terminus of dys-
trophin (lanes 5 and 6) or syntrophin (lanes 7 and 8) combined
with FLN2 fusion protein (lanes 5 and 7) or GST protein alone
(lanes 6 and 8). (B) Supernatants of the above reactions corre-
sponding to the respective lanes in A (lanes 1–8), showing that
translated product was present in all tubes.
Figure 4. In vitro analysis of the d-sarcoglycan interaction with
FLN2. FLN2 clone 2-14 was inserted into the transcription/trans-
lation vector pFHR3 that contains a seven amino acid flag-tag.
d-sarcoglycan was inserted into the transcription/translation vec-
tor pMGT1, which does not contain the flag-tag. 35S-labeled in
vitro translated products were incubated together and precipi-
tated with a specific antibody. After incubation with protein
G–Sepharose, the samples were washed three times with lysis
buffer (see Materials and Methods) and electrophoresis on a
4–20% SDS-PAGE gel. After electrophoresed, the gels were ex-
posed to a storage phosphor plate and the plate was scanned us-
ing a PhosphoImager. (lanes 1–4) Coimmunoprecipitation of
translated labeled FLN2 with labeled d-sarcoglycan using a
d-sarcoglycan antibody (lane 1); no antibody (lane 2); g-sarcogly-
can antibody (lane 3); M2 antibody (directed toward the flag-tag)
(lane 4). Lane 5 corresponds to translated labeled d-sarcoglycan
alone with M2 antibody. Lane 6 corresponds to translated la-
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show that nonspecific antibodies are unable to CoIP the
d-sarcoglycan or FLN2 proteins, respectively. Therefore,
in this system, FLN2 binds to d-sarcoglycan, and although
the  g-sarcoglycan translated product was not coimmu-
noprecipitated with FLN2, the possibility remains that
the binding between FLN2 and g-sarcoglycan is slightly
weaker than this method’s detection limits.
In Vivo Association of g- and d-Sarcoglycans
with FLN2
To further explore the association between FLN2 and the
sarcoglycans, anti–g- and anti–d-sarcoglycan antibodies
were used to CoIP g- and d-sarcoglycan immune com-
plexes from cultured mouse myotube lysates. The g-sar-
coglycan antibodies from Novocastra have been shown
previously to immunoprecipitate only g-sarcoglycan, and
the d-sarcoglycan antibodies have been shown to immuno-
precipitate only d- and b-sarcoglycans from mouse muscle
cell lysates (Chan et al., 1998). Antibodies raised against
FLN2, dystrophin, a-actinin 2, and a-, b-, g-, and d-sar-
coglycans were used to determine the presence or absence
of these proteins in the complexes. In the g-sarcoglycan
antibody immune complexes, only FLN2 and g-sarcogly-
can were detected (Fig. 5 A, lane 2). Dystrophin, a-actinin
2, and the other sarcoglycans were not detected in these
complexes. Immune complexes generated using d-sar-
coglycan antibodies revealed the presence of FLN2 and
b- and d-sarcoglycans (Fig. 5 B). The finding of b-sarcogly-
can in d-sarcoglycan immune complexes is not unexpected
as previous studies have shown b- and d-sarcoglycan to be
a tightly associated core complex (Chan et al., 1998).
These complexes did not contain dystrophin, a-actinin 2,
or a- or g-sarcoglycan. To test whether FLN2 protein
could be immunoprecipitated with just sarcoglycan anti-
body, anti–g-sarcoglycan antibodies were used to immu-
noprecipitate a cytoplasmic FLN2-rich soluble fraction in
which no g-sarcoglycan protein was present (see Fig. 6).
The anti–g-sarcoglycan antibodies were not able to precip-
itate FLN2 protein; however, using the FLN2 antibody as
a control to CoIP FLN2, FLN2 protein was immunopre-
cipitated from this fraction, indicating that the sarcogly-
can antibodies do not nonspecifically immunoprecipitate
FLN2 protein (Fig. 5 C, lanes 1 and 2). In the absence of
sarcoglycan antibodies, no FLN2 protein was detected,
suggesting that the FLN2 protein did not adhere directly
to protein G–Sepharose (Fig. 5 C, lane 4). In addition,
when the nonspecific antibody M2 was used to CoIP from
whole cell lysates, no FLN2 protein was detected (Fig. 5 C,
lane 6). Taken together, these data suggest that FLN2 can
be coimmunoprecipitated from mouse myotube lysates us-
ing g- and d-sarcoglycan antibodies, and that this interac-
tion is specific for FLN2 with the respective sarcoglycan
proteins.
Cellular Location of FLN2
FLN1 has been found to exist in two intracellular pools in
nonmuscle cells: one associated with the plasma mem-
brane and the other within the actin cytoskeletal network
(Gorlin et al., 1990; Sharma et al., 1995; Liu et al., 1997;
Meyer et al., 1997; Ott et al., 1998). Given the tremendous
amount of FLN2 in the crude lysate, the relatively small
amount of FLN2 associated with the sarcoglycans at the
membrane suggests that FLN2 might also be found in two
intracellular pools: a small fraction associated with the sar-
colemmal membrane and a larger intracellular portion. To
quantify the amount of FLN2 at the membrane, we pre-
pared fractionated microsomes from cultured mouse myo-
tubes and tested for the presence of FLN2 protein. After
several centrifugations, the final microsome pellet and the
resulting supernatant were separated by electrophoresis
on a 4–20% SDS-PAGE gel, and subsequently blotted
onto nitrocellulose membrane. Lane 1 of Fig. 6 represents
12.5% of total microsome protein, and lane 2 is 1.25% of
the protein content in the total soluble cytoplasmic frac-
tion. Using antibodies raised against various DGC mem-
bers, FLN2 and hsp70 (an intracellular protein), the com-
position of each fraction was determined. Densitometry
analysis was performed using the ImageQuant v1.1 soft-
ware (Molecular Dynamics) to determine approximate
percentages for each protein in the two fractions. Approx-
imately 3% of the total cellular FLN2 was found associ-
Figure 5. In vivo interaction of FLN2 with g- and d-sarcoglycan.
(A) Cultured mouse myotube lysates were used to coimmuno-
precipitate protein complexes using anti–g-sarcoglycan antibod-
ies. Approximately 25 mg of protein from total cell lysates was
separated by electrophoresis and blotted onto nitrocellulose
membranes (lane 1). g-Sarcoglycan antibody immune complexes
were washed three times with lysis buffer (see Materials and
Methods), separated by electrophoresis, and blotted onto nitro-
cellulose membranes (lane 2). Antibodies raised against various
DGC members were used to determine the presence or absence
of their respective proteins in each reaction. (B) In a similar ex-
periment as stated above, protein complexes were immunopre-
cipitated using anti–d-sarcoglycan serum. The doublet detected
for d-sarcoglycan is present in all experiments using the anti–
d-sarcoglycan antibodies presumably because this antibody was
not affinity-purified, and is recognizing the immunoglobulin
chains. (C) Controls for the coimmunoprecipitation experiments.
Lanes 1 and 2 contain supernatant from a microsome preparation
precipitated using either anti–FLN2 (lane 1) or anti–g-sarcogly-
can (lane 2) antibodies. Lanes 3–6 contain immune complexes
from cell lysates using either no antibody (lane 4) or a nonspe-
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ated with the membrane fraction and 97% with soluble
fraction. Comparing the FLN2 cell lysate signal in Fig. 5 A
with the microsome fraction in Fig. 6, it can be seen that
FLN2 is much more abundant in the total cell lysate, sup-
porting the quantitive analysis. Most of the other DGC
members were found associated with the microsome frac-
tion with the exception of syntrophin and a-dystroglycan,
which were also found in the soluble fraction. As a nega-
tive control, hsp70 was added to the analysis to ensure for
purity of microsome preparations, and as expected, was
found exclusively in the soluble fraction.
To further explore the subcellular location of FLN2, we
performed immunofluorescence microscopy, confocal mi-
croscopy, and immunoelectron microscopy studies. The
initial immunofluorescence microscopy studies suggested
that there were indeed two intracellular pools for FLN2
like that found for FLN1. A distinct banding pattern was
observed on longitudinal sections of normal adult skeletal
muscle that is characteristic for intermediate filament pro-
teins (Fig. 7 A). Cross-sections displayed a punctate pat-
tern throughout each myofiber representing the banded
pattern seen on longitudinal sections in addition to a clear
sarcolemmal staining (Fig. 7 B). Confocal microscopy
demonstrated staining predominantly within the contrac-
tile apparatus (presumably the Z-line) and at the sar-
colemmal membrane although the plasma membrane
staining is more diffuse than what has been previously
shown for other DGC members such as dystrophin (Fig.
8). Furthermore, the Z-line labeling appears to extend be-
yond the lateral limits of this structure. This finding may
be due to the ultimate limited diffraction resolution of the
confocal microscope (0.2 microns). To investigate this
finding further as well as confirm sarcolemmal membrane
staining, we performed EM analysis. By EM, the plasma-
lemmal labeling appeared to exist in two populations: one
population adjacent to the membrane and another more
diffuse (Fig. 9). In Fig. 9 A, labeling can be seen associated
with the cytoplasm at the intracellular aspect of the plasma
membrane (arrowheads), which is also seen in Fig. 9 B (ar-
row). The labeling of the Z-line within the muscle fiber is
clearly shown in Fig. 9 C where there is a sarcomere away
from the cell surface. No label is seen within the A band,
though considerable label is associated with the lateral
edges of the Z-line within the I band (arrows). An occa-
sional label is seen within the Z-line (arrowheads).
Analysis of FLN2 in Patients and gsg 2/2, dgs 2/2, 
and mdx Mice
Often a secondary instability of DGC members occurs
when there is a primary mutation in one of the proteins.
This is frequently seen with the sarcoglycan complex and
sarcospan when one sarcoglycan is altered (Bonnemann et
al., 1996; Duclos et al., 1998; Araishi et al., 1999). Since
FLN2 interacts with members of the sarcoglycan complex,
we reasoned that FLN2 might also be altered within the
muscle fiber. To assess FLN2 in LGMD2C, DMD patients
and an undetermined myopathy patient with an increased
CPK level and normal DGC member staining, we per-
formed IMF on muscle biopsies. All biopsies were previ-
Figure 6. Quantification of membrane-associated FLN2. Mi-
crosomes were prepared from cultured mouse myotubes, and
both the soluble and microsome fractions were separated by elec-
trophoresis and subsequently blotted onto nitrocellulose mem-
branes. Lane 1 represents 12.5% of the total protein content of
the microsome, and lane 2 represents 1.25% of the total protein
content of the soluble fraction. Antibodies for each protein were
used to determine the protein content for FLN2, a-, b-, g-, and
d-sarcoglycans, a- and b-dystroglycans, dystrophin, syntrophin,
and hsp70. The relative amount of FLN2 associated with the
membrane was determined to be z3% using the ImageQuant
v1.1 software.
Figure 7. Confocal analysis of FLM2-A2 shows a clear localiza-
tion within skeletal muscle. In cross-section, label appears
strongly associated with the plasma membrane of the muscle fi-
ber. While continuous, this label has a variable intensity (A)
along the perimeter of the fibers. For example, regions of high in-
tensity are highlighted (arrows). In longitudinal sections (B), a
strong association with the Z-line is apparent. A similar, though
slightly less intense label is also apparent at the plasma mem-
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ously screened for the sarcoglycans and dystrophin. Strik-
ingly, both LGMD patients tested and the DMD patient
had an observable FLN2 increase at the membrane when
compared with the normal (Fig. 10 A). In contrast, the pa-
tient with the unknown myopathy had no observable in-
crease of FLN2 at the muscle membrane. All of the
sarcoglycans and dystrophin were found to be normal
in this patient, suggesting that the FLN2 increase in
LGMD2C and DMD patients is specific for the sarcogly-
cans and dystrophin and not a general finding of myopa-
thies.
To determine whether this phenomenon could also be
seen in the null mice, we analyzed membrane preparations
from gsg 2/2, dsg 2/2, and mdx mice by Western blot
analysis. In all cases, the membrane bound FLN2 in-
creased to at least 25% (Fig. 10 B). In mdx membranes,
FLN2 was increased as much as 45%. These results sup-
port the patient results found by IMF.
Discussion
Although new genes and proteins are continuously identi-
fied that are involved in the dystrophic phenotype, the one
question that remains unanswered is the mechanism by
which this phenotype occurs. Several animal model sys-
tems are being developed to explore this question and,
through these models, it has become clear that the
sarcoglycans help in the maintenance of skeletal muscle,
although how this is accomplished remains elusive. In-
terestingly, although mutations in dystrophin and the
sarcoglycans produce a similar phenotype, dystrophin
staining in the sarcoglycanopathies is either normal or
slightly reduced, indicating that the selective loss of the
sarcoglycan complex is sufficient to cause muscular dys-
trophy.
Here, we describe the novel interaction between mem-
bers of the sarcoglycan complex and FLN2, a muscle-spe-
cific relative of filamin 1 (FLN1). We demonstrate that
both g- and d-sarcoglycan interact with FLN2 specifically
through in vivo and in vitro studies. In addition, we show
that FLN2 is located in two intracellular pools, with z3%
of the cellular content at the sarcolemmal membrane and
the remaining z97% contained within the cytoplasm, pre-
sumably at the Z-line of the contractile apparatus as seen
by EM. Strikingly, in LGMD patients, DMD patients, and
knockout mice lacking either g- or d-sarcoglycan, the
membrane component of FLN2 increases to z30%. In
contrast, in a patient with an undetermined myopathy,
FLN2 expression at the membrane appeared normal.
Filamin (ABP-280) was first identified in chicken giz-
zard and rabbit peripheral blood as a protein capable of
inducing actin polymerization (Hartwig and Stossel, 1975;
Wang et al., 1975). Subsequent biochemical and molecular
studies have shown that three different types of filamin
proteins exist in mammals (FLN1, b-FLN,  and a third
muscle-specific form, here named FLN2). Virtually all
cells express at least one filamin form at some point in de-
velopment, often changing forms as the cell undergoes ter-
minal differentiation (Stossel and Hartwig, 1975; Shizuta
et al., 1976; Maestrini et al., 1993; Takafuta et al., 1998).
All three filamins are encoded by separate genes: FLN1 is
located on chromosome Xq28; b-filamin is located on
chromosome 3p14.3-p21.1; and an EST, shown here to be
part of the FLN2 transcript, is located on chromosome
7q32-q35 (Gorlin et al., 1993; Maestrini et al., 1993).
Most reports of filamin function include a role in actin
polymerization, a process that is critical for the regulation
of the contractile apparatus in skeletal muscle as well as
cell structure, organization of membrane receptors with
signaling molecules, and mechanoprotection in other tis-
sues. These processes can regulate cell behavior by provid-
ing the cell with the information necessary for making
decisions regarding cell shape, adhesion and migration,
growth and differentiation, and apoptosis and survival. An
example of one of these processes is found in platelets,
where the transient binding of FLN1 to the GP Ib-IX re-
Figure 8. Immunoelectron microscopic analyses show two appar-
ent pools of label at the plasma membrane of muscle fibers (A)
labeling associated with the electron dense plasmalemmal cy-
toskeleton is seen (arrows) as well as within the cytoplasm adja-
cent to the plasmalemma (arrowheads). The plasmalemmal la-
beling is also apparent at the Z-line (B, arrow). However, in this
image, it is also clear that the label associated with the Z-line per-
sists right up to the plasma membrane (arrowhead). Labeling of
the Z-line is also detected within fibers away from the plasma
membrane, as shown in C. In this figure, the label can be seen to
be associated with the lateral aspect of the Z-line (arrows) al-
though occasional label within the Z-line is also apparent (arrow-
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ceptor complex has been shown to be important in platelet
activation by inducing changes in cellular shape, adhesion,
and membrane organization. Interestingly, the binding of
both of these proteins to the GP Ib-IX complex is depen-
dent on the stress-induced conformational change of the
receptor complex (Andrews and Fox, 1991; Andrews and
Berndt, 1998).
In addition to establishing cell structure and reorganiz-
ing receptor/signaling molecules, FLN1 also has been
shown to be crucial in protecting cells from external stress,
a process commonly referred to as mechanoprotection.
This phenomenon has been chiefly studied in fibroblasts
where FLN1 is recruited to integrin receptor complexes in
response to the stress-induced binding of ECM proteins.
Figure 9. FLN2 analysis of pa-
tients and null mice. (A) A–E
are cross-sections of skeletal
muscle biopsies. B–D are short
exposure times because of the
intense staining at the mem-
brane. F is a longitudinal section
of normal skeletal muscle ex-
posed for a longer period to
bring out Z-line pattern. All
panels are at a magnification of
40 except panel E, which is at 25.
B and C represent two different
LGMD 2C patients. (G) Ap-
proximately 40 mg of protein
from null mouse microsome
preparations was loaded in each
lane for Western analysis. The
designation gsg2/2 and dsg2/2
refers to the g-sarcoglycan and
d-sarcoglycan knockout mice, re-
spectively. Membranes were
probed with FLN2 antibodies (1:
2,500). Coomassie brilliant blue
staining was used to normalize
protein loading (data not
shown). FLN2 protein amounts
relative to the control animal
were analyzed using UN-SCAN-
IT™ software (Silk Scientific
Corporation).
Figure  10. LGMD model. Shown is a sche-
matic representing some proteins involved in
muscular dystrophy and how they might in-
teract with FLN2. Depending on the phos-
phorylation state of FLN2, it may be present
at the membrane or interacting with the actin
cytoskeleton. At the membrane, FLN2 inter-
acts with g- and d-sarcoglycan and possibly
with b1 integrin. One set of receptor signals
may recruit FLN2 to the membrane, whereas
another set of signals allows FLN2 to translo-
cate back to the actin cytoskeleton. Also de-
picted in this diagram is calpain-3, which may
help to regulate FLN2 levels within the cell.Thompson et al. Interaction of FLN2 with g- and d-Sarcoglycan 125
This signal triggers the rearrangement of the actin cyto-
skeleton to accommodate for the sensed tension. Remark-
ably, after force application, cells deficient for FLN1 show
membrane disruption and a .90% increase in cell death
compared with FLN1 containing cells (Glogauer et al.,
1998). Therefore, in the absence of FLN1, these cells are
unable to maintain membrane integrity when exposed to
external forces, ultimately leading to cell death.
With the identification of FLN2 as a sarcoglycan inter-
acting protein, the sarcoglycans join the list of proteins
that are both involved in signal transduction and the dys-
trophic phenotype. Moreover, this interaction connects
other proteins involved in dystrophy with the sarcoglycans
in a signaling process that has been extensively studied in
other systems, and is now unfolding in skeletal muscle.
Mutations in the integrin a7 subunit, a muscle-specific in-
tegrin, result in congenital myopathy (Vachon et al., 1997;
Hayashi et al., 1998), whereas mutations in calpain-3, ca-
veolin-3, and the sarcoglycans result in an LGMD pheno-
type. Family members of all three of these proteins have
been found to contribute in various signaling cascades.
Moreover, the integrins are also involved in mechanopro-
tection pathways in fibroblasts where they bind to FLN1
(Glogauer et al., 1998). Although these studies focus on
the a2 subunit, it has been established that both FLN1 and
b-FLN bind b1 integrin in other cells.
Given the data presented here and the known functions
of FLN1, a mechanistic model for some forms of muscular
dystrophy can be explored. The FLN2 membrane increase
in LGMD and DMD patients suggests that FLN2 is bind-
ing other membrane bound proteins other than the sar-
coglycans. A logical candidate for this second interacting
protein would be b1 integrin given that both of the other
filamin family members bind to this subunit in other cells.
If this is true, it is possible that the sarcoglycans and the in-
tegrins both bind FLN2 at the membrane (Fig. 10). FLN1
has been shown to bind a variety of receptors, validat-
ing this possibility. Signals received by the integrins might
recruit FLN2 to the membrane until a signal via the sar-
coglycans is received, thereby allowing FLN2 to translo-
cate back to the actin cytoskeleton. If selected components
of the DGC are missing from the membrane, integrin
bound FLN2 remains at the membrane failing to translo-
cate back to bind F-actin. Data from patient and mouse
studies support this scenario in which membrane bound
FLN2 goes from 3% (normal) to 20–40% in individuals
lacking either g-sarcoglycan, d-sarcoglycan, or dystrophin.
Another important connection between filamin proteins
and muscular dystrophy are the calpains. FLN1 is cleaved
by nonmuscle calpain to regulate actin-myosin filament
formation (Kwak et al., 1993a). Thus, the overall regula-
tion of FLN2 levels could be accomplished by the muscle-
specific calpain, calpain-3. To date, no substrate has been
identified for calpain-3, leaving FLN2 as an attractive can-
didate.
In summary, the identification of the interaction be-
tween FLN2 and the sarcoglycans should help in establish-
ing a more definitive function for the sarcoglycan complex
in skeletal muscle. It was originally believed that the DGC
had simply a structural role in the maintenance of skeletal
muscle by anchoring muscle cells to the extracellular ma-
trix (Campbell, 1995). Examination of FLN2 and several
proteins involved in the dystrophic phenotype reveals that
it is more likely a dynamic process such as signal transduc-
tion. Furthermore, as a new member of the dystrophin–
glycoprotein complex, FLN2 becomes a candidate disease
gene in LGMD patients who do not have mutations in any
of the known LGMD genes. Recently, two LGMD fami-
lies were reported to be genetically linked to chromosome
7q to a region that may include FLN2 (Speer et al., 1999).
Thus, it will be interesting to determine if these patients
have disease causing mutations in FLN2.
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